

Corvus Pharmaceuticals, Inc.  
Form 8-K  
June 28, 2018

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**  
**Date of Report (Date of earliest event reported): June 28, 2018**

---

**CORVUS PHARMACEUTICALS, INC.**  
**(Exact name of registrant as specified in its charter)**

---

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-37719**  
**(Commission**  
**File Number)**

**46-4670809**  
**(IRS Employer**  
**Identification Number)**

**863 Mitten Road, Suite 102**  
**Burlingame, CA 94010**  
**(Address of principal executive offices, including Zip**  
**Code)**

**Registrant's telephone number, including area code: (650) 900-4520**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ]
- [  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ]
- [  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ]
- [  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- ]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ X ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ X ]

---

**Item 7.01. Regulation FD Disclosure.**

On June 28, 2018, Corvus Pharmaceuticals, Inc. issued a press release announcing publication of results of preclinical studies of CPI-444 conducted by researchers at Johns Hopkins University School of Medicine. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Security Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

<b><u>Exhibit</u></b> <b><u>No.</u></b>	<b><u>Description</u></b>
99.1	<u>Press Release titled, “Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in <i>Cancer Immunology, Immunotherapy</i>” dated June 28, 2018</u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORVUS PHARMACEUTICALS, INC.**

Date: June 28, 2018

By: /s/ Leiv Lea  
Leiv Lea  
Chief Financial Officer